Biomind Labs Inc.
BMNDF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $8 | $15 | $42 | $28 |
| Gross Profit | -$8 | -$15 | -$42 | -$28 |
| % Margin | – | – | – | – |
| R&D Expenses | $16 | $313 | $574 | $571 |
| G&A Expenses | $379 | $662 | $2,316 | $2,828 |
| SG&A Expenses | $379 | $682 | $2,316 | $2,828 |
| Sales & Mktg Exp. | $0 | $20 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Expenses | $396 | $994 | $2,891 | $3,399 |
| Operating Income | -$396 | -$976 | -$2,891 | -$3,399 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $135 | -$216 | -$95 | -$933 |
| Pre-Tax Income | -$260 | -$1,192 | -$2,986 | -$4,332 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$260 | -$1,214 | -$2,986 | -$4,332 |
| % Margin | – | – | – | – |
| EPS | -0.003 | -0.016 | -0.04 | -0.06 |
| % Growth | 79% | 59.4% | 33.5% | – |
| EPS Diluted | -0.003 | -0.016 | -0.04 | -0.06 |
| Weighted Avg Shares Out | 76,163 | 74,762 | 74,762 | 72,060 |
| Weighted Avg Shares Out Dil | 76,146 | 74,762 | 74,762 | 72,060 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $31 | $164 | $1 | $4 |
| Depreciation & Amortization | $9 | $15 | $42 | $28 |
| EBITDA | -$396 | -$1,035 | -$2,891 | -$3,399 |
| % Margin | – | – | – | – |